Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterization study
Armin Mooranian, Rebecca Negrulj, Nigel Chen-Tan, Hesham S Al-Sallami, Zhongxiang Fang, Trilochan Mukkur, Momir Mikov, Svetlana Golocorbin-Kon, Marc Fakhoury, Frank Arfuso, Hani Al-Salami
Drug Design, Development and Therapy | DOVE MEDICAL PRESS LTD | Published : 2014
Gliclazide (G) is an antidiabetic drug commonly used in type 2 diabetes. It has extrapancreatic hypoglycemic effects, which makes it a good candidate in type 1 diabetes (T1D). In previous studies, we have shown that a gliclazide-bile acid mixture exerted a hypoglycemic effect in a rat model of T1D. We have also shown that a gliclazide-deoxycholic acid (G-DCA) mixture resulted in better G permeation in vivo, but did not produce a hypoglycemic effect. In this study, we aimed to develop a novel microencapsulated formulation of G-DCA with uniform structure, which has the potential to enhance G pharmacokinetic and pharmacodynamic effects in our rat model of T1D. We also aimed to examine the effec..View full abstract
The authors acknowledge the CHIRI at Curtin University, the Curtin-seeding grant for support, and the use of equipment and scientific and technical assistance of the Curtin University Electron Microscope Facility, which has been partially funded by the university, and state and Commonwealth governments.